AbbVie Inc.
AbbVie Elects CEO as New Chairman
Summary
AbbVie Inc. announced on February 13, 2025, that its Board of Directors elected CEO Robert A. Michael as the new Chairman, effective July 1, 2025. Richard A. Gonzalez, the current Chairman, will retire on the same date. Additionally, Glenn F. Tilton will retire from the board. The changes were disclosed in a press release on February 14, 2025.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement